Intensity Therapeutics, Inc.
INTS
$3.96
-$0.04-1.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.46% | 32.52% | -16.84% | -22.71% | -37.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.57% | -1.97% | -23.45% | -46.64% | -28.44% |
| Operating Income | 25.57% | 1.97% | 23.45% | 46.64% | 28.44% |
| Income Before Tax | 27.28% | 4.09% | 23.97% | 48.96% | 27.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.28% | 4.09% | 23.97% | 48.96% | 27.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.28% | 4.09% | 23.97% | 48.96% | 27.29% |
| EBIT | 25.57% | 1.97% | 23.45% | 46.64% | 28.44% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 82.58% | 76.29% | 75.61% | 62.91% | 34.30% |
| Normalized Basic EPS | 82.58% | 76.28% | 75.61% | 62.91% | 34.30% |
| EPS Diluted | 82.58% | 52.54% | 75.61% | 62.91% | 34.30% |
| Normalized Diluted EPS | 82.58% | 76.28% | 75.61% | 62.91% | 34.30% |
| Average Basic Shares Outstanding | 317.52% | 304.48% | 211.79% | 37.59% | 10.67% |
| Average Diluted Shares Outstanding | 317.52% | 304.48% | 211.79% | 37.59% | 10.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |